미국 · 보도자료 · GKOS · 2026-10-08 11:00
망막질환 치료제 RO-104 글로벌 독점 라이선스 계약
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a novel tri-specific biologic for the treatment of n
